Sagimet Biosciences (SGMT) Operating Income (2022 - 2026)
Sagimet Biosciences (SGMT) posted quarterly Operating Income of -$11.7 million for Q1 2026, up 41.04% year-over-year from -$8.3 million in Q1 2025, and down 8.81% quarter-over-quarter from -$10.8 million in Q4 2025.
Sagimet Biosciences (SGMT) Operating Income (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Operating Income history runs 5 years deep, the most recent figure standing at -$11.7 million for Q1 2026.
- In Q1 2026, Operating Income rose 41.04% year-over-year to -$11.7 million; the TTM figure through Mar 2026 stood at -$48.7 million (up 25.65% YoY), while the FY2025 annual figure was -$56.9 million, down 4.47% from the prior year.
- Operating Income for Q1 2026 stood at -$11.7 million, down from -$10.8 million in the prior quarter.
- The five-year high for Operating Income was -$6.8 million in Q1 2023, with the low at -$19.9 million in Q1 2025.
- The 5-year median for Operating Income is -$10.0 million (2023), against an average of -$11.0 million.
- The sharpest annual moves came in 2024 and 2026: Operating Income slumped 126.81% in 2024, then soared 41.04% in 2026.
- Sagimet Biosciences' Operating Income stood at -$7.4 million in 2022, then declined by 28.13% to -$9.5 million in 2023, then sank by 92.21% to -$18.2 million in 2024, then soared by 40.84% to -$10.8 million in 2025, then fell by 8.81% to -$11.7 million in 2026.
- Business Quant data shows SGMT's Operating Income at -$11.7 million in Q1 2026, -$10.8 million in Q4 2025, and -$14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Sagimet Biosciences | 649.79 Mn | 649.79 Mn | - | -15.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.82 Mn |
| Mar 31, 2026 | -11.71 Mn |
| Dec 31, 2025 | -10.77 Mn |
| Sep 30, 2025 | -14.33 Mn |
| Jun 30, 2025 | -11.93 Mn |
| Mar 31, 2025 | -19.87 Mn |
| Dec 31, 2024 | -18.20 Mn |
| Sep 30, 2024 | -16.90 Mn |
| Jun 30, 2024 | -10.59 Mn |
| Mar 31, 2024 | -8.77 Mn |
| Dec 31, 2023 | -9.47 Mn |
| Sep 30, 2023 | -7.45 Mn |
| Jun 30, 2023 | -7.06 Mn |
| Mar 31, 2023 | -6.77 Mn |
| Dec 31, 2022 | -7.39 Mn |
| Sep 30, 2022 | -7.69 Mn |
| Jun 30, 2022 | -7.24 Mn |